Novo Nordisk further lowers prices for weight loss, diabetes drugs for those who pay cash

Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk announced Monday that it is lowering prices for its blockbuster obesity and diabetes drugs for cash-paying patients.

​ Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk announced Monday that it is lowering prices for its blockbuster obesity and diabetes drugs for cash-paying patients. Read More Breaking News, Latest News and Videos | CNN